ADMA BIOLOGICS, INC. Total Liabilities
ADMA BIOLOGICS, INC. (ADMA) had Total Liabilities of $276.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-05
- 2026-06-30: Liabilities $276.00M.
- 2026-03-31: Liabilities $274.86M.
- 2025-12-31: Liabilities $146.92M.
- 2025-09-30: Liabilities $137.50M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $276.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $274.86M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $146.92M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $137.50M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $160.06M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $137.15M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $139.66M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $158.73M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $188.13M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $197.17M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $193.98M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $197.56M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $196.26M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $195.13M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $196.49M 10-K · filed 2024-02-28 | $196.49M 10-K · filed 2023-03-23 |
| 2022-09-30 | $200.17M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $182.53M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $181.10M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $135.08M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $135.86M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $121.22M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $123.16M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $119.42M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $118.60M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $114.66M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $114.19M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $100.90M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $101.66M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $96.37M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $68.08M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $69.11M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $69.14M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $65.99M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $68.11M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $67.69M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $59.82M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $56.96M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $28.35M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | $28.14M 10-K · filed 2018-03-29 | |
| 2016-09-30 | $27.65M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $27.83M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | $23.05M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $22.89M 10-K · filed 2017-02-24 | |
| 2015-09-30 | $22.91M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $20.28M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $20.50M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $21.01M 10-K · filed 2016-03-23 | $21.22M 10-K · filed 2015-03-09 |
| 2014-09-30 | $16.04M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $15.58M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $16.05M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $10.41M 10-K · filed 2015-03-09 | |
| 2013-09-30 | $9.44M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $8.96M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $7.42M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | $6.13M 10-K · filed 2014-03-28 | |
| 2012-09-30 | $1.62M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $1.23M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $1.26M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $2.54M 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |